BAN2401 is a prototype Alzheimer's drug that originally traces back to BioArctic Neuroscience, a Swedish biopharmaceutical company. Japan's Eisai licensed the drug's approach from BioArctic and is now working together with Boston-based Biogen for the joint development of BAN2401. The drug itself is a therapeutic antibody that binds to large, soluble amyloid beta protofibrils (amyloid beta is the main component of the amyloid plaques that are found in the brains of Alzheimer's patients). The developers of the drug hope that its initial beneficial effects – shown in mice to reduce the toxicity of amyloid beta protofibrils and to protect neural cells – will also be evident in the humanized version of the antibody, which is being studied now via clinical trials.
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)